Status: Not yet recruiting
Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study
This is a prospective, multicenter, observational study aimed at exploring the efficacy and safety of reduced-dose chemotherapy followed by frontline therapy with blinatumomab in patients aged 15-65 with newly diagnosed Ph-negative B-ALL.
Participants needed: 36
Trial details
Age: 15-65Biological sex: AllType: ObservationalSponsor: Shandong UniversityUpdated: Oct 18, 2024
Eligibility criteria
Age 15-65 years, both male and female are eligible; [+5]
Previous or ongoing systemic anti-acute lymphoblastic leukemia (ALL) treatment (... [+12]